-+ 0.00%
-+ 0.00%
-+ 0.00%

KELUN-BIOTECH ANNOUNCES PHASE III STUDY OF SACITUZUMAB TIRUMOTECAN (SAC-TMT) IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PD-L1-NEGATIVE NON-SQUAMOUS NSCLC MET PRIMARY ENDPOINT

Reuters·07/14/2026 23:30:00

Please log in to view news